Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished. We examined the cost-per-outcome implications of util...

Descripción completa

Detalles Bibliográficos
Autores principales: Alnsasra, Hilmi, Tsaban, Gal, Solomon, Adam, Khalil, Fouad, Aboalhasan, Enis, Azab, Abed N., Azuri, Joseph, Hammerman, Ariel, Arbel, Ronen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436293/
https://www.ncbi.nlm.nih.gov/pubmed/37601066
http://dx.doi.org/10.3389/fphar.2023.1227199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436293/
https://www.ncbi.nlm.nih.gov/pubmed/37601066
http://dx.doi.org/10.3389/fphar.2023.1227199

Ejemplares similares